Inspire Pharmaceuticals’ proposed treatment for cystic fibrosis is advancing to Phase III clinical trials.

Inspire (Nasdaq: ISPH) said it recently had a successful meeting with the Food and Drug Administration about results of its Phase II work.

Inspire has already conducted six studies with more than 300 patients and volunteers for the drug denufosol.

Inspire sees denufosol as an early intervention therapy for treatment of patients with mild lung disease.

Two studies are expected to be launched this year, one to determine efficacy and the other to study inhalation carcinogenicity.